Opioid Agonist Treatment (OAT)
Speaker script · 10-minute presentation
Slide 1 – Title (~15 sec)
Good morning everyone. My name is [your name], and today I’ll be presenting on Opioid Agonist
Treatment, commonly known as OAT – one of the most widely used and best-evidenced treatments
for opioid dependence.
Slide 2 – Introduction (~45 sec)
To give you an overview: opioid dependence is a chronic, relapsing condition that carries a very high
risk of overdose and premature death. OAT is a pharmacological treatment that helps manage that
dependence. In this presentation I’ll cover three things. First, what OAT actually is and how it
developed. Second, how the main medications – methadone and buprenorphine – work to reduce
harm. And third, I’ll critically evaluate the evidence base, looking at how effective OAT is across
mortality, retention in treatment, and access. I’ll finish with the key takeaways and what they mean
for clinical practice.
Slide 3 – Description: Origins & development (~75 sec)
Let’s start with what OAT is and where it came from. OAT – also called medication-assisted
treatment of opioid dependence, or MATOD – works by replacing illicit, short-acting opioids like
heroin with a long-acting opioid that is prescribed and taken under supervision. The approach dates
back to the 1960s, when Vincent Dole and Marie Nyswander in New York pioneered methadone
maintenance. Their work was significant because it reframed opioid dependence as a treatable
medical condition, rather than a moral failing or something to be solved through willpower alone.
Buprenorphine, a partial opioid agonist, came later, and together with methadone it is now listed by
the World Health Organization as an essential medicine. To give a sense of scale, in Australia today
more than fifty thousand people are receiving OAT, delivered through a nationally regulated
treatment framework.
Slide 4 – Description: Main features (~75 sec)
So how does it actually work in practice? There are two main medicines. Methadone is a full opioid
agonist, and buprenorphine is a partial agonist, which is often combined with naloxone to reduce the
risk of misuse. Both work in a similar way: they relieve withdrawal symptoms and craving, and they
block the euphoric effects of other opioids. Crucially, this allows a person to stabilise their life
without being intoxicated. Treatment is usually delivered as supervised dosing – daily at first – at a
pharmacy or clinic, with take-away doses introduced as the person becomes more stable. There is
also now a long-acting injectable form of buprenorphine, which removes the burden of daily dosing.
One important point: OAT works best when the medication is paired with psychosocial and medical
support – it is most effective as part of a package of care, not as medication alone.
Slide 5 – Evaluation: Mortality & overdose (~80 sec)
Now to the evidence – and this is where OAT is genuinely impressive. Starting with mortality. A large
2021 systematic review and meta-analysis by Santo and colleagues, published in JAMA Psychiatry,
found that being in OAT roughly halves both all-cause and overdose mortality. It also reduces deaths
from drug-related causes, suicide, and cardiovascular disease, and it is especially protective during
and after release from prison – a notoriously high-risk period. But there are important caveats. The
same evidence shows that the first four weeks of methadone induction carry a temporarily elevated
mortality risk, because the dose is still being titrated. And critically, risk rises sharply when people
stop treatment – up to six times higher in the first month after cessation. The clear message is that
the protective benefit depends on staying in treatment; early dropout removes that protection.
Slide 6 – Evaluation: Retention & functioning (~70 sec)
Beyond mortality, OAT performs well on other outcomes. The landmark Cochrane review by Mattick
and colleagues showed that methadone retains far more people in treatment and reduces heroin
use compared with no opioid replacement. Retention matters, because staying engaged is what
keeps people safe. OAT also reduces injecting frequency, and with it the transmission of blood-borne
viruses like HIV and hepatitis C. And it improves day-to-day functioning – employment and
relationships – while reducing criminal activity. That said, it is not without limitations. Daily
supervised dosing can be burdensome and, for some, stigmatising. Not everyone achieves
abstinence, and some people frame OAT as simply substituting one drug for another. There are also
genuine safety concerns around diversion, which is why careful dosing and monitoring are essential.
Slide 7 – Evaluation: Access & equity (~65 sec)
The third evaluative lens is access and equity. On the positive side, OAT is cost-effective and
recommended in both Australian and global clinical guidelines. The range of options – methadone,
buprenorphine, and now depot injections – means treatment can be tailored to individual needs.
And importantly, it engages a marginalised population in ongoing healthcare they might otherwise
avoid. But access remains a real problem. Globally, coverage is low and unevenly distributed. Cost,
travel, and strict dosing requirements create barriers, particularly for people in rural areas. And
stigma – both anticipated and experienced – deters many people from starting treatment, and from
staying in it. So the evidence for effectiveness is strong, but that benefit can only be realised if
people can actually get, and stay on, treatment.
Slide 8 – Conclusion (~50 sec)
To bring this together. First, OAT is an evidence-based, life-saving treatment that substantially
reduces mortality and harm for people with opioid dependence. Second, its benefits depend on
retention – and induction and cessation are the higher-risk periods that need careful, person-
centred support. Third, to get the most out of OAT, we need to pair the medication with
psychosocial care, improve access, and actively reduce the stigma that keeps people away.
Slide 9 – Application & close (~40 sec)
So what does this mean in practice? It means offering OAT early, and without judgement, to people
with opioid dependence. It means supporting patients carefully through induction and avoiding
abrupt, unplanned cessation. And it means combining OAT with harm-reduction measures, like take-
home naloxone, and with psychosocial support. Thank you very much for listening – I’m happy to
take any questions.
Slides 10–11 – References
These slides list the APA references for all evidence cited throughout the presentation; no spoken
script is required.